# CB-839 in Combination With Niraparib in Platinum Resistant BRCA -Wild-type Ovarian Cancer Patients

> **NCT03944902** · PHASE1 · TERMINATED · sponsor: **University of Alabama at Birmingham** · enrollment: 1 (actual)

## Conditions studied

- Ovarian Cancer
- Resistant BRCA Wild-Type Ovarian Cancer

## Interventions

- **DRUG:** Cohort 1: Dose Escalation
- **DRUG:** Cohort 2: Dose Escalation

## Key facts

- **NCT ID:** NCT03944902
- **Lead sponsor:** University of Alabama at Birmingham
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-09-01
- **Primary completion:** 2022-01-05
- **Final completion:** 2022-01-05
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** will not resume. company choosing not to continue with drug. one participant now off study.
- **Last updated:** 2023-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03944902

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03944902, "CB-839 in Combination With Niraparib in Platinum Resistant BRCA -Wild-type Ovarian Cancer Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03944902. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*